Back
RiverNorth Capital and Income Fund Vs. Apogee Therapeutics, Inc. Industry Stock Comparison
Sell
35
RSF
RiverNorth Capital and Income Fund
Last Price:
$14.85
Seasonality Move:
-0.25%
Sell
44
APGE
Apogee Therapeutics, Inc.
Last Price:
$84.40
Seasonality Move:
-11.77%
Sell
35
RiverNorth Capital and Income Fund (RSF)
is a Sell
Is RiverNorth Capital and Income Fund a Buy, Sell or Hold?
-
The current RiverNorth Capital and Income Fund [RSF] share price is $14.70. The Score for RSF is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.
-
RSF is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
44
Apogee Therapeutics, Inc. (APGE)
is a Sell
Is Apogee Therapeutics, Inc. a Buy, Sell or Hold?
-
The current Apogee Therapeutics, Inc. [APGE] share price is $84.34. The Score for APGE is 44, which is 12% below its historic median score of 50, and infers higher risk than normal.
-
APGE is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
RSF Stock Price Chart
What is RiverNorth Capital and Income Fund's stock price today?
-
The RiverNorth Capital and Income Fund share price today is $14.70Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and RSF is experiencing selling pressure, which indicates risk of future bearish movement.
APGE Stock Price Chart
What is Apogee Therapeutics, Inc.'s stock price today?
-
The Apogee Therapeutics, Inc. share price today is $84.34Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and APGE is experiencing buying pressure, which is a positive indicator for future bullish movement.
RSF Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.05 | Buy |
| Relative Strength Index (14 RSI): | 54.54 | Buy |
| Chaikin Money Flow: | -6926 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (14.34 - 14.72) | Buy |
| Bollinger Bands (100): | (14.37 - 14.63) | Buy |
APGE Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 3.18 | Buy |
| Relative Strength Index (14 RSI): | 64.96 | Buy |
| Chaikin Money Flow: | 432550 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (69.1 - 79.44) | Buy |
| Bollinger Bands (100): | (66.23 - 78.47) | Buy |
RSF Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 14.64 | Buy |
| 20-day SMA: | 14.58 | Buy |
| 50-day SMA: | 14.49 | Buy |
| 200-day SMA: | 14.6 | Buy |
| 8-day EMA: | 14.63 | Buy |
| 20-day EMA: | 14.58 | Buy |
| 50-day EMA: | 14.53 | Buy |
| 200-day EMA: | 14.64 | Buy |
APGE Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 79.91 | Buy |
| 20-day SMA: | 75.21 | Buy |
| 50-day SMA: | 71.36 | Buy |
| 200-day SMA: | 57.28 | Buy |
| 8-day EMA: | 80.37 | Buy |
| 20-day EMA: | 76.41 | Buy |
| 50-day EMA: | 73.33 | Buy |
| 200-day EMA: | 61.58 | Buy |
RiverNorth Capital and Income Fund Earnings Growth & RSF Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Apogee Therapeutics, Inc. Earnings Growth & APGE Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.08 per share, a decrease next quarter of $0.21 per share, a decrease this year of $0.63 per share, and a decrease next year of $0.62 per share.
RiverNorth Capital and Income Fund Technical Analysis
| Mar 20 | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 30 | Mar 31 | Apr 1 | Apr 2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | Apr | |||||||||
| 20 | 23 | 24 | 25 | 26 | 27 | 30 | 31 | 01 | 02 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Apogee Therapeutics, Inc. Technical Analysis
| Mar 20 | Mar 23 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | Mar 30 | Mar 31 | Apr 1 | Apr 2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | Apr | |||||||||
| 20 | 23 | 24 | 25 | 26 | 27 | 30 | 31 | 01 | 02 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||